Damien Delzer, OD
Optometrist · Fairbanks, AKNPI 1346228517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations.
Across 53 payments — averaging $47.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$400
- Bausch & Lomb Americas Inc.$278
- Tarsus Pharmaceuticals, Inc.$269
- AbbVie$246
- Regeneron Healthcare Solutions, Inc.$244
- Oyster Point Pharma, Inc.$211
- plus $861 from 12 others
What the payments were for
- Consulting fees$201%
- Food & beverage$2,49099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 5 | $400 |
| Bausch & Lomb Americas Inc. | 6 | $278 |
| Tarsus Pharmaceuticals, Inc. | 2 | $269 |
| AbbVie(2 entities) | 10 | $246 |
| Regeneron Healthcare Solutions, Inc. | 2 | $244 |
| Oyster Point Pharma, Inc. | 5 | $211 |
| Dompe US, Inc. | 2 | $158 |
| Amgen | 3 | $157 |
| Sun Pharmaceutical Industries Inc. | 3 | $128 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $122 |
| Mallinckrodt Hospital Products Inc. | 2 | $73 |
| Aerie Pharmaceuticals, Inc. | 3 | $44 |
| ANI Pharmaceuticals, Inc. | 1 | $42 |
| Novartis | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Shire North American Group Inc | 1 | $24 |
| Coopervision Inc. | 1 | $20 |
| Quidel Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,510 in reported general payments places this provider in the 85th percentile of 163 optometrist providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 74 | $54,213 |
| LumiganBimatoprost | 72 | $52,782 |
| CequaCyclosporine | 51 | $47,696 |
| Cyclosporine | 61 | $40,495 |
| RestasisCyclosporine | 26 | $35,962 |
| MieboPerfluorohexyloctane/Pf | 25 | $35,478 |
| TyrvayaVarenicline Tartrate | 14 | $19,117 |
| Brimonidine Tartrate | 38 | $13,562 |
| RhopressaNetarsudil Mesylate | 13 | $9,751 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 29 | $8,266 |
| TafluprostTafluprost/Pf | 17 | $6,990 |
| Loteprednol Etabonate | 26 | $6,945 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $6,609 |
| Timolol Maleate | 126 | $3,037 |
| Latanoprost | 161 | $2,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $246 | $95,354109 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $278 | $89,69199 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $128 | $47,69651 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $211 | $19,11714 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $44 | $9,75113 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $122 | $6,94526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 163 optometrist providers in Alaska.
Other optometrist in Fairbanks
- Barbara KeysFairbanks$4K
- Terry BellFairbanks$4K
- Laura LangfordFairbanks$2K
- Michael MavencampFairbanks$2K
- Danica LantzFairbanks$2K
- Mark LantzFairbanks$2K
- Scott AmestoyFairbanks$2K
- Jeremy FulkFairbanks$2K
- Marvin AcquistapaceFairbanks$953
- Natalie MackeFairbanks$856
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.